Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy

Prostate

Volumn 61, Issue 3, 2004, Pages 267-275

  Williams, Heinric ^a   Powell, Isaac J ^a   Land, Susan J ^a   Sakr, Wael A ^a   Hughes, Mark R ^a   Patel, Nimesh P ^a   Heilbrun, Lance K ^a   Everson, Richard B ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Genetic polymorphisms; Prognosis; Prostate cancer; Racial disparity; Vitamin D receptor

Indexed keywords

VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RACE; RECURRENCE RISK; SURVIVAL;

AFRICAN AMERICANS; AGED; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; SURVIVAL ANALYSIS;

EID: 5344230111     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20103     Document Type: Article

References (52)

1. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Mariotto A, Fay M, Feuer E, Edwards BE, editors. SEER cancer statistics review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5-26.
3. Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W, Grignon DJ, Wood DP. Disease-free survival difference between African-Americans and whites after radical prostatectomy for local prostate cancer: A multivariable analysis. Urology 2002;59(6): 907-912.
4. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155:1667-1672.
5. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst 1998;90(13):986-990.
6. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001;93(3):219-225.
7. Freedland SJ, Dorey F, Aronson WJ. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy. Urology 2000;56(5):807-811.
8. Fowler JJ, Bigler SA, Farabaugh PB, Wilson SS. Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less then 4 ng/ml. J Urol 2000;164(6):1961-1963.
9. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000;163(1):143-145.
10. Eastham JA, Carver B, Katz J, Kattan MW. Clinical stage T1c prostate cancer: Pathologic outcomes following radical prostatectomy in black and white men. Prostate 2002;50(4):236-240.
11. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10(5A): 1307-1311.
12. Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvala H, Lou YR, Ahonen M, Hasan T, Pasanen P, Blauer M, Manninen T, Miettinen S, Vilja P, Ylikomi T. Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001;76(1-5):125-134.
13. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50(6):999-1006.
14. 3 on primary cultures of human prostatic cells. Cancer Res 1994;54(3):805-810.
15. Miller GJ. Vitamin D and prostate cancer: Biologic interactions and clinical potentials. Cancer Metastasis Rev 1998;17(4):353-360.
16. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14(3A):1077-1081.
17. 3. Endocrinology 1995;136(1):20-26.
18. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132(5): 1952-1960.
19. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165(4):1319-1324.
20. 3. Prostate 1995;26(2):72-79.
21. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003;88(2):363-371.
22. Martin JL, Pattison SL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 2000;141(7):2401-2409.
23. Sarma AV, Jaffe CA, Schottenfeld D, Dunn R, Montie JE, Cooney KA, Wei JT. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: Clinical correlates of prostate volume among black men. Urology 2002; 59(3):362-367.
24. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51 (Suppl 3):34-41.
25. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 2003;35(11-12):726-733.
26. 3 (calcitriol). J Urol 1998;159(6):2035-2039; discussion, 2039-2040.
27. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1(9):997-1003.
28. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001;2(2):203-216.
29. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13(3):325-349.
30. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89(2):166-170.
31. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiologic Rev 2000;22(2): 203-217.
32. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, Yu MC, Ross RK, Coetzee GA. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies. Cancer Epidemiol Biomarkers Prev 1997;6(2):93-98.
33. Hustmyer FG, DeLuca HF, Peacock M. ApaI, BsmI, EcoRV, and TaqI polymorphisms at the human vitamin D receptor gene locus in Caucasians, blacks, and Asians. Hum Mol Genet 1993;2(4):487.
34. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-activating factor alleles to normal physiological variability: Vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992;89:6665-6669.
35. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56(18):4108-4110.
36. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12(3):182-196.
37. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12(12):1395-1402.
38. Sakr WA, Grignon DJ. Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Urol Clin North Am 1999;26(3):453-463.
39. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system, 2nd edn. Cary, NC: SAS Institute, Inc; 2000.
40. Allison PD. Survival analysis using the SAS system: A practical guide. Cary, NC: SAS Institute, Inc.; 1995.
41. Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 2001;82(4):566-572.
42. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126(1):83-90.
43. Issa LL, Leong GM, Sutherland RL, Eisman JA. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002;17(5):879-890.
44. Cottone E, Orso F, Biglia N, Sismondi P, De Bortoli M. Role of coactivators and corepressors in steroid and nuclear receptor signaling: Potential markers of tumor growth and drug sensitivity. Int J Biol Markers 2001;16(3):151-166.
45. Murphy S, Weigel NL. 1Alpha,25-Dihydroxyvitamin D3 induced growth inhibiton of pC-3 prostate cancer cells requires and active transforming growth factor beta signnaling pathway. Prostate (Early View Online Publication) 2004.
46. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003;133(Suppl 7):2461S-2469S.
47. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2(5):467-472.
48. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6(3): 235-239.
49. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5(2):121-126.
50. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9(4):425-432.
51. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92(24):2009-2017.
52. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC. Susceptibility to prostate cancer: Studies on interactions between UVR exposure and skin type. Carcinogenesis 2003;24(4):711-717.